VasoRx is pioneering RNA therapies for the treatment of cardiovascular diseases, specifically targeting pulmonary hypertension and coronary artery disease. The company leverages groundbreaking discoveries from MIT and Yale to develop effective and safe RNA interference (RNAi) and messenger RNA (mRNA) therapies. VasoRx focuses on selective gene silencing and overexpression in vascular endothelium, aiming to address fibrosis, vascular remodeling, and chronic vascular inflammation.
VasoRx has made significant strides in translating innovative RNA therapy technologies for lipid nanoparticle (LNP) delivery systems. These advancements position the company at the forefront of cardiovascular disease treatment, potentially transforming patient outcomes. The collaboration with prestigious institutions like MIT and Yale underscores the scientific rigor and potential impact of their therapies.
